GRAIL (GRAL) to Release Quarterly Earnings on Tuesday

GRAIL (NASDAQ:GRAL) is projected to announce its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of ($2.7629) per share and revenue of $39.1550 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. The company had revenue of $43.60 million during the quarter, compared to analyst estimates of $43.33 million. On average, analysts expect GRAIL to post $-12 EPS for the current fiscal year and $-11 EPS for the next fiscal year.

GRAIL Price Performance

NASDAQ GRAL traded down $0.41 during mid-day trading on Monday, reaching $53.65. The stock had a trading volume of 142,582 shares, compared to its average volume of 1,125,609. GRAIL has a 1 year low of $29.95 and a 1 year high of $118.84. The stock has a market cap of $2.30 billion, a PE ratio of -4.80 and a beta of 3.03. The company has a fifty day moving average price of $50.32 and a 200 day moving average price of $78.86.

Insider Buying and Selling at GRAIL

In other news, CFO Aaron Freidin sold 45,806 shares of the business’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the sale, the chief financial officer owned 260,669 shares of the company’s stock, valued at $13,012,596.48. The trade was a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Robert P. Ragusa sold 123,502 shares of the business’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the sale, the chief executive officer directly owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 310,267 shares of company stock worth $15,485,396.

Institutional Investors Weigh In On GRAIL

Hedge funds have recently modified their holdings of the business. Comerica Bank grew its position in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares during the period. Intesa Sanpaolo S.p.A. bought a new stake in shares of GRAIL during the 4th quarter valued at $44,000. Ankerstar Wealth LLC bought a new stake in shares of GRAIL during the 4th quarter valued at $45,000. Rossby Financial LCC grew its position in shares of GRAIL by 25.0% during the 4th quarter. Rossby Financial LCC now owns 1,250 shares of the company’s stock valued at $107,000 after acquiring an additional 250 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in shares of GRAIL by 244.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,610 shares of the company’s stock valued at $95,000 after acquiring an additional 1,142 shares during the period.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on GRAL shares. Guggenheim decreased their price objective on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Mizuho assumed coverage on shares of GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective for the company. TD Cowen upgraded shares of GRAIL from a “hold” rating to a “buy” rating and set a $65.00 target price for the company in a research note on Wednesday, March 18th. Wall Street Zen lowered shares of GRAIL from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Finally, Canaccord Genuity Group decreased their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $68.63.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.